MX2022013934A - Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo. - Google Patents

Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.

Info

Publication number
MX2022013934A
MX2022013934A MX2022013934A MX2022013934A MX2022013934A MX 2022013934 A MX2022013934 A MX 2022013934A MX 2022013934 A MX2022013934 A MX 2022013934A MX 2022013934 A MX2022013934 A MX 2022013934A MX 2022013934 A MX2022013934 A MX 2022013934A
Authority
MX
Mexico
Prior art keywords
cov
protein
sars
newcastle disease
spike protein
Prior art date
Application number
MX2022013934A
Other languages
English (en)
Inventor
Peter Palese
Florian Krammer
Adolfo Garcia-Sastre
Weina Sun
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/022848 external-priority patent/WO2021194826A2/en
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of MX2022013934A publication Critical patent/MX2022013934A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se describen virus de la enfermedad de Newcastle recombinantes ("NDVs") que comprenden un genoma empaquetado, en donde el genoma empaquetado comprende un transgén que comprende una secuencia de nucleótidos que codifica para una proteína de espícula o proteína de nucleocápside del SARS-CoV-2. También se describen en el presente documento NDVs recombinantes que comprenden un genoma empaquetado, en donde el genoma empaquetado comprende un transgén que codifica para una proteína F quimérica, en donde la proteína F quimérica comprende un ectodominio de proteína de espícula del SARS-CoV-2 y dominios citoplásmico y de transmembrana de la proteína F del NDV. Los NDVs recombinantes y sus composiciones son útiles para la inmunización contra el SARS-CoV-2 así como para la prevención de la COVID-19.
MX2022013934A 2020-05-07 2021-05-06 Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo. MX2022013934A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063021677P 2020-05-07 2020-05-07
US202063051858P 2020-07-14 2020-07-14
US202063057267P 2020-07-27 2020-07-27
US202063058435P 2020-07-29 2020-07-29
US202063059924P 2020-07-31 2020-07-31
PCT/US2021/022848 WO2021194826A2 (en) 2020-03-24 2021-03-17 Recombinant sars-cov-2 spike protein and uses thereof
PCT/US2021/031110 WO2021226348A2 (en) 2020-05-07 2021-05-06 Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof

Publications (1)

Publication Number Publication Date
MX2022013934A true MX2022013934A (es) 2023-02-22

Family

ID=78468787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013934A MX2022013934A (es) 2020-05-07 2021-05-06 Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.

Country Status (7)

Country Link
US (1) US20230310583A1 (es)
EP (1) EP4146674A2 (es)
JP (1) JP2023524990A (es)
BR (1) BR112022022604A2 (es)
CA (1) CA3178875A1 (es)
MX (1) MX2022013934A (es)
WO (1) WO2021226348A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113881704B (zh) * 2021-11-17 2024-02-13 浙江迪福润丝生物科技有限公司 一种包含新型冠状病毒双抗原靶标序列组合的重组新城疫病毒载体及相应疫苗株和疫苗
CN114196701B (zh) * 2021-11-17 2023-10-10 浙江迪福润丝生物科技有限公司 一种sars-cov-2的二价重组新城疫病毒载体及相应疫苗株和制备方法
CN114213547A (zh) * 2021-12-16 2022-03-22 浙江迪福润丝生物科技有限公司 一种展示新冠s蛋白的融合蛋白和重组病毒粒子及其应用
WO2023173032A2 (en) * 2022-03-10 2023-09-14 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
WO2023196759A2 (en) * 2022-04-03 2023-10-12 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) * 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów

Also Published As

Publication number Publication date
WO2021226348A3 (en) 2021-12-09
EP4146674A2 (en) 2023-03-15
WO2021226348A2 (en) 2021-11-11
US20230310583A1 (en) 2023-10-05
BR112022022604A2 (pt) 2023-03-28
JP2023524990A (ja) 2023-06-14
CA3178875A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2022013934A (es) Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
WO2023056351A3 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
Robison et al. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly
von Messling et al. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity
Kubo et al. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein
CN1989250B (zh) Tc-83衍生的甲病毒属载体、颗粒和方法
Shi et al. Visualizing the replication cycle of bunyamwera orthobunyavirus expressing fluorescent protein-tagged Gc glycoprotein
JP3961222B2 (ja) Ｐｒｒｓｖワクチン
CN103442731B (zh) 表达系统
Pugachev et al. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection
Shi et al. Role of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesis
EA200801501A1 (ru) Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
JP2006136340A (ja) 組換え伝染性非セグメント化陰性鎖ｒｎａウイルス
Du et al. Efficient replication and generation of recombinant bovine adenovirus‐3 in nonbovine cotton rat lung cells expressing I‐SceI endonuclease
US10849969B2 (en) Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
US20130071429A1 (en) Bunyavirus vaccine
JPH03503364A (ja) フラビウイルスに起因する病気を予防するための組換え体ワクシニアウイルス
Navaratnarajah et al. A structurally unresolved head segment of defined length favors proper measles virus hemagglutinin tetramerization and efficient membrane fusion triggering
Wessel et al. Human monoclonal antibodies against NS1 protein protect against lethal West Nile virus infection
Bosch et al. Coronavirus spike glycoprotein, extended at the carboxy terminus with green fluorescent protein, is assembly competent
Mittler et al. The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection
BR0112020A (pt) Partìculas tipo vìrus de bvdv
WO2023196759A3 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
WO2023173032A3 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
MX2022016502A (es) Proteinas quimericas de rsv y coronavirus, composiciones inmunogenicas y metodos de uso.